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18%; MDS 17%; NHL 33%. These data show: no signiﬁcantly
difference in the patients outcome between BM or PB SC; auto
SCT has a low transplant related morbi-mortality. The higher
relapse rate in ALL and ST was in the ﬁrst year, and AML and
Lym in the ﬁrst 4 years, then the survival curve reaches a plateau,
so the remaining patients should be cured. The tandem SCT in
MM lets see a signiﬁcantly better overall survival at 10 years. Lym
that relapse after the ﬁrst auto-SCT can beneﬁt from a second
transplant with similar survival that obtained after ﬁrst auto-SCT,
although a bigger number of patient is required to conclude deﬁ-
nitely. We think higher ALL overall survival than the literature
reports, is in relationship with the maintenance treatment. We
emphasize the allo-SCT higher mortality, without relapse after
ﬁrst year except in MDS. Randomized protocols to evaluate main-
tenance treatment pos SCT and non-mieloablatives allo-SCT are
now in development.
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AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH
ACUTE MYELOID LEUKEMIA IS RELATIVELY SAFE AND PROVIDES
LONG-TERM DISEASE CONTROL
Ganguly, S.1, Divine, C.L.1, Deauna-Limayo, D.1, Bodensteiner, D.C.1,
Lewis, J.L.1, Curran, K.1, Skikne, B.S.1 University of Kansas Medical
Center, Kansas City, KS.
Autologous stem cell transplantation (ASCT) in patients with
acute myeloid leukemia (AML) is often used as a consolidation
therapy after attaining morphologic and cytogenetic remission.
ASCT is often the only option when a suitable donor is not
available for patients who needed further intensiﬁcation of treat-
ment. In an attempt to examine whether ASCT provides long-term
disease control in patients with AML, we retrospectively evaluated
our experience and analyzed the outcomes of ASCT in patients
with AML from 1986 to 2005. Twenty-three males and 26 females
(n  49) of median age 44 years (range 15–68 years) were treated.
Of these, 42 were in CR at the time of transplantation, and 7
patients were transplanted with active disease. Thirty-three pa-
tients were transplanted in ﬁrst remission. Bone marrow was used
in 26 patients as the source of stem cells prior to 1995 and
peripheral blood stem cells (PBSC) were used in 20 patients. Three
patients received a combination of marrow and PBSC. Forty-eight
of 49 patients engrafted (96%). Median time for neutrophil recov-
ery was 17.5 days (range 9–69 days) and 42 days (range 16–303
days) for platelets. Patients who received PBSC achieved granulo-
cyte and platelet engraftments earlier than patients who received
bone marrow as the source of stem cells. Median duration of
follow-up was 8.5 years (range 29 days–18 years). Of the 49 pa-
tients, 32 had died. Five patients (9%) died within 100 days of
transplantation. Overall survival (OS) and disease-free survival
(DFS) of all evaluable patients were 27% and 33%, respectively.
Median duration of response was 11.4 months. No relapses oc-
curred after 2.2 years. OS and DFS in patients transplanted in CR
were 32% and 38%, respectively. For those transplanted with
disease (n  7), a complete response was achieved in 4 patients
(57%), with a median survival of 166 days. Disease status at trans-
plantation was a signiﬁcant variable for survival (P  .01). Most
frequent cause of death was disease relapse (19 out of 32 patients).
Two patients developed late onset myelodysplastic syndrome. In
conclusion, ASCT in patients with AML in whom an allogeneic
transplantation is not feasible appears to be a safe alternative and
provides long-term disease control.
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A REVIEW OF THE USE OF TOPOTECAN FOR MOBILIZATION OF PE-
RIPHERAL BLOOD STEM CELLS IN AUTOLOGOUS HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Pring, K.1, Hale, G.1, Barﬁeld, R.1, Horwitz, E.1, Kasow, K.1,
Leung, W.1, Woodard, P.1, Yusuf, U.1, Handgretinger, R.1 St Jude
Children’s Research Hospital, Memphis, TN.
Topotecan is an active agent in many pediatric malignancies. For
patients with high risk malignancies for whom consolidation with
autologous hematopoietic stem cell transplantation is an option,
the use of topotecan for mobilization of hematopoietic progenitor
cells is promising. However, there are limited published data on
topotecan as a mobilizing agent in pediatric patients with solid
tumors. We retrospectively reviewed the medical records of ap-
proximately 90 patients undergoing autologous hematopoietic
stem cell transplantation from December 2001 to December 2004
at our institution. We identiﬁed patients who received topotecan
with the purposes of collecting peripheral blood progenitor cells
after its administration. These patients had the following diseases:
Neuroblastoma, Ewings/PNET, and Wilms tumor. Some patients
did have evidence of bone marrow involvement prior to hemato-
poietic stem cell collection. Topotecan was administered at a dose
of 0.75–2 mg/m2/day on days 1–5. GCSF at 10 mcg/kg/day was
administered starting 1 day after the completion of chemotherapy.
Eight of the 17 patients failed to mobilize peripheral blood pro-
genitor cells. Following a nadir of the absolute neutrophil count,
peripheral blood CD34 counts were monitored once the ANC
reached 500/cm. Once the absolute peripheral blood CD34 count
met or exceeded 20, apheresis was performed. Nine patients un-
derwent apheresis and had an adequate number of peripheral blood
CD34 cells collected. The median CD34 collection was 6.495 
106 CD34/kg (range 1.806–9.895). All these patients subse-
quently went on to autologous hematopoietic stem cell transplan-
tation using a variety of conditioning regimens. All patients en-
grafted post transplant. Patients with early stage disease such as
neuroblastoma may have sufﬁcient numbers of peripheral blood
cells following topotecan mobilization. This data suggests that
topotecan is an active agent for mobilization of peripheral blood
cells in newly diagnosed or minimally treated patients.
285
HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANS-
PLANTATION (ASCT) IN HODGKIN’S DISEASE (HD) WITH >2 RE-
LAPSES—TATA MEMORIAL HOSPITAL DATA
Sastry, P.S.R.K.1, Narayanan, P.1, Bakshi, A.1, Bhagwat, R.1,
Biswas, G.1, Khadwal, A.1, Mishra, B.K.1, Parikh, P.M.1 Tata Memo-
rial Hospital, Mumbai, Maharashtra, India.
Background: Relapsed or refractory Hodgkin’s Disease (HD)
patients have a poor prognosis with standard salvage chemother-
apy, yielding a cure rate of 20% or less. High dose chemotherapy
followed by ASCT is an accepted salvage treatment in relapsed
Hodgkin’s Disease with improvement in Disease Free and Overall
Survival. We present our experience with ASCT in Hodgkin’s
Disease in patients who had 2 or more relapses. Patients and
Methods: A total of 19 patients have undergone ASCT for HD
over a period of 12 years. There were 15 males and 4 females.The
source of stem cells was Peripheral Blood in all the 19 cases. The
conditioning regimen used was BEAM in 13 (68%) and ICE in 6
(32%). Results: The median age was 28 years. The median num-
ber of relapses pre ASCT were 2.3 (range 2–4) and the median
time for ﬁrst relapse after initial chemotherapy was 24 months.
The median time from ﬁrst relapse to ASCT was 29 months.After
a median follow-up of 16.5 months, 63% of patients are alive
(overall survival) with no evidence of disease in 53% (disease free
survival). The Transplant Related Mortality (TRM) is 10%. Con-
clusions: ASCT is an effective salvage treatment in multiply re-
lapsed Hodgkin’s Disease with acceptable TRM and good disease
free and overall survival.
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PREVENTION OF MUCOSITIS IN AutoBMT/STEM CELL TRANSPLANT
PATIENTS
Klocke, J.1, Cannon, M.1, Devoe, C.1, Gissinger, D.1, John, V.1,
Bayer, R.-L.1 North Shore University Hospital, Manhasset, NY.
It is estimated that 80% of patients who undergo high-dose
chemotherapy / radiotherapy prior to transplantation develop
mucositis. Mucositis is a painful complication, which can lead to
poor nutrition, increased use of narcotics, dehydration, greater risk
for infection and bacteremia, and altered quality of life. Patients
can have oral ulceration, epigastric discomfort, diarrhea, rectal
irritation, and bleeding. It is likely that the complications of mu-
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cositis can contribute to increased length of stay during stem cell
transplantation. The purpose of this study is to compare patients
who received Kepivance® (palifermin) as part of their treatment
with patients who did not receive this medication regimen during
autologous stem cell transplantation. We performed a retrospec-
tive analysis of 40 patients; 20 prior to the institution of Kepiv-
ance® (palifermin), and 20 patients after. The preparative regimens
include Melphalan, Busulfan and Etoposide and Etoposide and
Cytoxan and BCNU and Etoposide. The average length of stay for
non-Kepivance patients was 32.3 days compared to 28.3 days in
patients who received the drug. The severity of both oral and GI
mucositis appeared to be less. Seventeen out of 20 non-Kepivance
patients experienced diarrhea or rectal irritation versus 9 out of 20
with Kepivance. Neutropenic fever was prevalent in both groups.
There was a trend toward earlier engraftment in the Kepivance
group. Kepivance seems to have had a positive effect for our
patients. This pilot study suggests an improvement in mucositis
symptoms with the use of Kepivance® (palifermin). It appears that
mucositis and its treatment contribute to the length of stay and
costs of stem cell transplantation. Quality of life for these patients
can be greatly improved if mucositis is eliminated or reduced
during the course of stem cell transplantation.
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HERTH HOPE SCALE ASSESSMENT IN SCCA TRANSPLANT PATIENTS
Rochester, J.M.1, Berry, D.L.1 Seattle Cancer Care Alliance, Seattle,
WA.
Significance: In order to help patients maintain or restore hope,
nurses nurture and promote hope. They help patients seek out
accurate information for a path to a better future. No efﬁcient or
systemic method has been applied in the transplant setting to date.
The Herth Hope Scale has been used in the context of homeless
families, older adults in the community and institutional settings,
in terminally ill patients, and people with ﬁrst recurrence of cancer.
Objective: Describe distribution of scores on the Herth Hope
Scale in a convenient sample of transplant patients. Eligibility:
Autologous Hematopoietic Stem Cell Transplant Patients. Meth-
ods: In a convenience sample of 30 patients, the Herth Hope Scale
was offered as a clinical assessment tool. Patients answered the
questionnaire on paper. No identiﬁers were recorded on the tool
nor were the results linked in any way to the patients’ records or
other data. The Herth Hope Scale data will be entered and ana-
lyzed with descriptive statistics in order to evaluate the score
distribution. This is an ongoing study through December 2005,
with the ﬁnal results in February 2006.
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PARTIAL MATURATION AND ROBUST EX VIVO EXPANSION OF UMBIL-
ICAL CORD BLOOD (UCB) T CELLS: A STEP TOWARDS ADOPTIVE
IMMUNOTHERAPY AFTER UCB TRANSPLANTS
Mazur, M.A.1, Lee, Y.A.1, Kurtzburg, J.1, Szabolcs, P.1 Duke Uni-
versity Medical Center Pediatric Blood and Bone Marrow Transplant,
Durham, NC.
Background: Viral infections cause signiﬁcant morbidity and
mortality in patients receiving unrelated umbilical cord blood
(uUCB) transplants as there is no established antiviral immunity in
naive UCB lymphocytes available for adoptive transfer. Addition-
ally, UCB T cells lack Th1/Tc1 cytokines, granzymes, and per-
forin, which are prerequisites to control viral pathogens. Another
limitation of UCB transplantation is the unavailability of donor T
cells for post-transplant donor leukocyte infusions (DLI) to boost
immunity or induce GVL. Still, a small fraction of the UCB graft
could be set aside for ex vivo T cell expansion. We tested the
hypothesis that UCB T cells could be expanded to cell doses
suitable for DLI and that they may mature acquiring a phenotype
compatible with effector function as assessed by expression of key
cytokines and members of the granzyme-perforin pathway. Meth-
ods: Thawed UBC research samples with a T cell content 3% of
an average UCB graft were processed. T cells were puriﬁed with
“EasySep” (StemCell Technologies) and 5–11  105 T cells/ml
were incubated in gas permeable bags with “CD3/28 T cell Ex-
pander” artiﬁcial APC beads (Dynal) in 10% human serum replete
media  200u/ml IL-2. Media and cytokines were replenished 3
times per week to maintain a concentration of  2  106 cells/ml.
Results: After 14 days UCB T cells expanded 72 fold  39 (mean,
SD), n  9. There was signiﬁcant evolution in phenotype over this
time (Table 1) with up to 40% of T cells entering the cell cycle
(Ki-67). The majority of expanded cells have acquired the phe-
notype of activated (HLA-DR, CD25, CD45RO) memory
cells, at the expense of naive/recent thymic immigrants
(CD45RA/CD62L). The CD4/CD8 ratio became inverted due
to the higher expansion rate of CD8 T cells (P  .0078) with no
difference in apoptosis (activated Casp-3, P  .188). Notably, all
T cells retained expression of CD28 and CD27. Granzymes A and
B and cytokine expression was acquired during expansion but
remained below normal adult peripheral blood values. However,
effector cytotoxic T cells with perforin or CD57 expression were
undetected. Conclusions: From our results we can demonstrate
effective expansion and partial maturation of UCB T Cells. Start-
ing with 2  106 total T cells, 73-fold expansion could provide for
DLI 6  106 T cells/kg for an average pediatric patient (25 kg).
In summary, ex vivo expansion could provide clinically relevant
number of partially mature T cells for adoptive immunotherapy
(Table 1).
Table 1. Characterization of Expanded T Cells as % of all Lymphocytes
Variable Median SD
CD3 99.8 0.4
CD4 38.7 9.3
CD4/CD8 2.3 2.3
CD28 98 6.9
CD45RA/RO 8.5 14.9
CD45RO/RA 47.8 23.4
CD25 57.2 22.2
CD45RA/CD62 54.5 22.7
CD45RA/CD27/CD8 59 16.4
CD45RA/CD27/CD8 39.4 17.2
KI67/CD8 38.8 11
KI67/CD4 30.4 11.4
HLA DR 39.3 17.5
Granzyme A/CD8 48 17
Granzyme B/CD8 4.9 4.2
Perforin/CD8 0 0
INF/CD3 1.9 5.6
TNF	/CD3 6.7 25.4
IL2/CD3 5.4 13.9
IL4/CD3 0 0
Act Caspase 3/CD4 11.7 8.9
Act Caspase 3/CD8 12.3 14.3
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HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) USING UM-
BILICAL CORD BLOOD UNITS (UCB) NOT DEPLETED OF RED BLOOD
CELLS PRIOR TO CRYOPRESERVATION
Chow, R.1, Nademanee, A.2, Rosenthal, J.2, Karanes, C.2,
Jaing, T.-H.3, Tan, P.4, Graham, M.5, Gjertson, D.6, Petz, L.1 1.
StemCyte International Cord Blood Center, Arcadia, CA; 2. City of
Hope National Medical Center, Duarte, CA; 3. Chung Gung Memorial
Hospital, Linko, Taiwan; 4. Mount Elizabeth Hospital, Singapore, Sin-
gapore; 5. University of Arizona Medical Center, Tuscon, AZ; 6. UCLA
Medical Center, Los Angeles, CA.
UCB is a promising source for HSCT; however, limiting cell
dose has hampered its widespread use. The red cell depletion
(RCD) techniques that are widely used incur signiﬁcant nucleated
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